Nasdaq apls.

25 сент. 2023 г. ... Apellis Pharmaceuticals (NASDAQ:APLS) announced Monday that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent ...

Nasdaq apls. Things To Know About Nasdaq apls.

Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com. Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. …CRESTWOOD, Ky., and WALTHAM Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...Envestnet Asset Management Inc. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 2.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,305 shares of the company’s stock after acquiring an additional 561 shares during the quarter. Envestnet Asset Management […]

WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...

On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...

WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ...Empaveli is also approved in Europe under the brand name Aspaveli for the same indication. The drug continues to be one of the growth drivers for Apellis, with …WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug Administration (FDA) has accepted Apellis’ unsolicited major amendment to the New Drug Application (NDA) for intravitreal …Nov 24, 2023 · Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s stock price traded down 3.7% on Wednesday after an insider sold shares in the company. The stock traded as low as $47.20 and last traded at $47.55. 370,506 shares changed hands during trading, a decline of 86% from the average session volume of 2,690,365 shares. The stock […] Nov 29, 2023 · That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ...

WALTHAM, Mass. and STOCKHOLM, Sweden, June 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced that the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy, in primary immune-complex …

WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its first ...

The latest price target for . Apellis Pharmaceuticals (NASDAQ: APLS) was reported by Goldman Sachs on November 9, 2023.The analyst firm set a price target for $74.00 expecting APLS to rise to ...Feb 22, 2023 · WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced ... Get the latest Apellis Pharmaceuticals Inc (APLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Shares of Apellis Pharmaceuticals ( APLS 6.66%) were down more than 9% on Wednesday, after falling as much as 12% earlier in the day. The company's shares fell following a short-seller report on ...9,367,396. 841,461. 11.1323. Back to APLS Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...WALTHAM Mass. and CRESTWOOD, Ky., March 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...3 дня назад ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags.

About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Nasdaq MarketSIte. Do Not Sell My Personal Information (CA ...WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S ...Our analysis of options history for Apellis Pharmaceuticals APLS revealed 35 unusual trades. Delving into the details, we found 62% of traders were bullish, while 37% showed bearish tendencies ...WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and ...Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved t...

WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and ...

The firm increased its portfolio allocation in APLS by 653.58% over the last quarter. VGHCX - Vanguard Health Care Fund Investor Shares holds 5,895K shares representing 5.01% ownership of the company.Dec 1, 2023 · 14 analysts have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they anticipate the company's share price to reach $66.50 in the next twelve months. This suggests a possible upside of 8.0% from the stock's current price. JPMorgan upgraded Apellis Pharmaceuticals (NASDAQ: APLS) to Overweight from Neutral, with a new price target of $81, up from $60 per share in a note Friday. Analysts told investors the Syfovre ...WALTHAM Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...WALTHAM, Mass. and STOCKHOLM, Sweden, June 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced that the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy, in primary immune-complex …Over the past 3 months, 10 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Open this page to get detailed information about APLS traded on NasdaqGS exchange in United States. ... NASDAQ DM Ex Japan Large Mid CaNQDMXJPLMAUD, 2100.38 AUD ...

Follow. WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that four oral ...

We challenge conventional thinking and always question if there's a better way. Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology ...

Nov 2, 2023 · Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ... CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Shares of Apellis Pharmaceuticals Inc (NASDAQ: APLS) declined following a report by Citron Research casting doubts on the company's prospects and the safety of its recently approved treatment for ...APLS NASDAQ. APLS NASDAQ. APLS NASDAQ. APLS NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials Technicals . Forecast . Price target. 71.19 0.00 0.00%. The 16 analysts offering 1 year price forecasts for APLS have a max estimate of — and a min estimate of —. Analyst rating. Based on 17 …Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has dropped by -3.62 in relation to previous closing price of 49.36. Nevertheless, the company has seen a loss of -1.71% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-09 that FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating […]NEW YORK, Aug. 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) alleging ...WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 30 months of continuous treatment with ...Nov 2, 2023 · Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ... 9 de set. de 2023 ... Fintel reports that on September 8, 2023, B of A Securities maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral ...CRESTWOOD, Ky., and WALTHAM Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...

Hedge funds poured into Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in even greater numbers during Q2, as the number of funds long APLS rose by 27% to reach a new all-time high and propel it to ...Get the latest Apellis Pharmaceuticals Inc (APLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.See historical performance and comparison. View Valuation. Research Apellis Pharmaceuticals' (Nasdaq:APLS) stock price, latest news & stock analysis. Find …Dec 4, 2023 · Apellis Pharmaceuticals Stock Down 1.9 %. Shares of NASDAQ:APLS opened at $60.40 on Monday. The company’s fifty day moving average price is $46.23 and its 200 day moving average price is $55.22. Instagram:https://instagram. nyse pwrpath stock buy or sellsprout stockoff price retailers Feb 21, 2023 · WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2022 financial results and business highlights. Over the past 3 months, 10 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with ... best emerging markets etfsare the bicentennial quarters worth anything SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS PR Newswire - Fri Sep 29, 3:28PM CDT /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS). Such...Nov 20, 2023 · Shares of NASDAQ APLS opened at $49.10 on Friday. The stock has a market cap of $5.82 billion, a P/E ratio of -9.35 and a beta of 0.97. The company has a current ratio of 4.29, a quick ratio of 3.76 and a debt-to-equity ratio of 0.40. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75. vanguard total corporate bond etf APLS Quantitative Stock Analysis. June 27, 2023 — 12:04 pm EDT. Written by John Reese for Validea ->. Below is Validea's guru fundamental report for APELLIS PHARMACEUTICALS INC ( APLS). Of the ...Find the latest Institutional Holdings data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ...